The usefulness of chemotherapy with S-1 for Japanese patients with non-small-cell lung cancer based on CYP2A6*4 gene polymorphism

点击翻译按钮获取中文摘要

The frequencies of the CYP2A6^*4C was 17.4%. In the S-1 pharmacokinetic analysis, the area under the concentration-time curve from 0 to 10 hours (AUC) ratios of 5-FU/tegafur showed large interindividual variabilities, ranging from 5.14 to 112.6. The AUC for tegafur was 1.5-fold higher in patients with the CYP2A6^*4C allele than in patients without the CYP2A6^*4C allele. Patients with the CYP2A6^*4C allele had a significantly lower maximum plasma concentration for 5-FU than patients without the CYP2A6^*4C allele.